Mednet Logo

Do you counsel patients on the risk of dementia following androgen deprivation therapy for prostate cancer?

Two retrospective studies from Stanford showed that patients who received ADT had an increased risk of dementia and Alzheimer's. Is this finding significant enough to discuss with patients prior to starting ADT? If so, how do you approach this discussion?
Community PollStarted

Do you counsel patients on the risk of dementia or memory loss following androgen deprivation therapy for prostate cancer?

81 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Cedars-Sinai Medical Center
Answered on

No, I generally do not counsel men about this risk. The two studies from the same investigator use a data warehouse search algorithm that may not be accurate enough to fully characterize who gets Alzheimer's disease or may not be able to correct for confounding factors that may be different between ...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Duke University School of Medicine
Answered on

Yes, I do counsel men on this risk. The absolute risk increase appears low (<1-2%) at 5 years, but the relative risk increase (about 2-fold) is concerning, and appears to be dose/duration related, suggesting a causal relationship. Since we do not understand the causes of Alzheimer's disease or which...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Medical Oncology · MSKCC
Answered on

I think that the jury is still out on this association, at least based on the recent literature. The methodology used by Nead et al, JAMA Oncol. 2016 Oct 13, raises some questions in my mind. Most importantly, their study did not control for stage of disease, which I would expect to be a very import...

Join for free or sign in to see the full answer